Testing a new drug added to chemoradiation for head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer (like in the throat, voice box, mouth, or sinuses) that has not spread to other parts of the body.
- Your doctor plans to treat you with the standard chemotherapy drug cisplatin and radiation therapy together.
- You are able to swallow pills without help.
- You are generally in good health—able to do light activity and take care of yourself (ECOG 0 or 1).
- You do not have diabetes that requires insulin, and your blood sugar levels are well controlled.
- You have not had chemotherapy, radiation, or major surgery for this specific cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
This trial studies whether adding cisplatin (a chemotherapy medicine) to radiation therapy helps people with stage III–IVA squamous cell cancer of the head and neck after they’ve had surgery. It’s meant to lower the risk of the cancer coming back.
This study tests whether adding the drug camonsertib to radiation therapy can help people whose head and neck cancer has come back in a spot that was already treated with radiation. Camonsertib is an experimental drug that may help radiation work better.
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
This Phase 1 trial tests a new plan that combines immunotherapy with surgery, plus a targeted radiation treatment called IORT. It is for people whose head and neck squamous cell cancer has come back or never fully went away and can be operated on. The goal is to shrink or control the cancer and see how safe the approach is.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.